designing mabs

In the past, Phylogica has been promoted as the technology that will replace ‘Monoclonal Antibodies’(mAb). In presentations, Watt has highlighted the endless number of applications where Phylomers with the diversity only nature could create, should out-perform engineered mAbs, small molecules and engineered peptides.

In hindsight, I’d suggest this strategy had a major flaw.
Watt didn’t allow for the drug industry’s long lasting love affair with monoclonal antibodies. mAb’s have been, a huge money earner and pharma appear to be comfortable in developing future drugs with the technology.

So where is Phylogica positioned at present?

Currently Hopkins’ main focus is on the ‘Endosomal Escape Trap’ technology, that finds ‘cell-penetrating peptides’ that enter specific areas of a cell. Linking these peptides to active mAbs, creates a mAb that will pass through the cell wall and fight disease within.

Now, instead of competing against the highly successful mAb industry, Phylogica are working with pharma in the design of mAbs.
SoT